PHILADELPHIA, PA, USA I September 9, 2015 I Spark Therapeutics, Inc. (ONCE) today announced database lock for the Phase 3 clinical trial of its lead program, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies. The datasets have been transferred to the company’s independent external statistical consultants, who have initiated the analysis of the data. Spark anticipates that it will provide top-line results in October.

“Locking the database marks an important step toward the completion of our Phase 3 trial and puts us in a position to share top-line results in October,” said Jeffrey D. Marrazzo, Co-founder and Chief Executive Officer of Spark.

In addition, Spark reported the following modifications to its final SAP:

  • Designation of pupillary light reflex as an exploratory endpoint and the analysis of the mobility test change score for an assigned first eye as a secondary endpoint, resulting in three secondary endpoints — full-field light sensitivity threshold testing, the first eye mobility test change score, and visual acuity — which will be tested hierarchically in that order; and
  • Adjustment to the intent-to-treat (ITT) population (n=31), which will be the main efficacy analysis population, as well as addition of a modified ITT population (n=29) and clarification of a per-protocol population (n=28), both of which will be used as sensitivity efficacy analysis groups.

“The modifications we have made to our final SAP will help create a more robust dataset by increasing the overall amount of information derived from the Phase 3 trial, now including certain pre-specified sensitivity analyses,” continued Mr. Marrazzo. “As we prepare to receive the data and present top-line results, we remain confident in the trial and believe the steps we have disclosed today will produce an improved data package to support future regulatory filings.”

Spark management will provide an update on the SPK-RPE65 program, including a review of the final Phase 3 SAP, during a conference call scheduled for tomorrow, September 10, 2015, at 8:30 am ET (details below).

Conference Call Details

The conference call can be accessed by dialing (855) 851-4526 (domestic) or +1 (720) 634-2901 (international) and entering passcode 33689474. To access a live audio webcast, please visit the “Investors” section at

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or +1 (404) 537-3406 (international) and entering passcode 33689474 or by visiting our website.

About Spark Therapeutics

Spark is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating orphan diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully enrolled pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark is leveraging the experience and technology utilized in the development of SPK-RPE65 to address a broad spectrum of blinding conditions, starting with the development of SPK-CHM for the potential treatment of choroideremia, currently in a Phase 1/2 clinical trial. Spark also is establishing a pipeline of gene therapy candidates to treat hematologic disorders and neurodegenerative diseases, including through a global collaboration with Pfizer Inc. around the development and commercialization of its SPK-FIX program for the treatment of hemophilia B. Spark’s integrated gene therapy platform builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit

SOURCE: Spark Therapeutics